High expression of USP22 predicts poor prognosis and advanced clinicopathological features in solid tumors: a meta-analysis

• DOI: 10.2147/ott.s148662
• Publication Date: 2018-05-22T19:49:26Z
• Authors: Xiaohui Yang; Haiyang Zang; Yingbin Luo; Jianchun Wu; Zhihong Fang; Weikang Zhu; Yan Li
• Keywords: 0301 basic medicine; 03 medical and health sciences; OncoTargets and Therapy; Original Research; 3. Good health

Introduction: The expression of USP22 has been demonstrated to play a pivotal role in solid tumors. However, the prognostic value still remains unknown. Materials and methods: A systematic meta-analysis was performed assess cancers. literature collection conducted from inception June 8, 2017 by searching PubMed, Cochrane Library, Embase, Ovid Web Science databases. pooled hazard ratio (HR) odds (OR) were used correlate high with overall survival (OS) clinicopathological features. Results: results, 19 studies 2,876 cases, indicated that predicted poor OS (HR=2.48, 95% CI: 2.11–2.84, p <0.001) disease-free (DFS; HR=2.55, 2.05–3.05, cancer patients. Furthermore, also significantly associated advanced parameters, including tumor stage, differentiation, metastasis, nodal status size. Conclusion: Our finding revealed might be an indicator prognosis features tumors could served as novel biomarker. Keywords: carcinoma, USP22, prognosis, biomarker,